A Glimpse Into The Expert Outlook On Health Catalyst Through 6 Analysts
Portfolio Pulse from Benzinga Insights
Analysts have mixed ratings for Health Catalyst (NASDAQ:HCAT), with most being somewhat bullish. The average 12-month price target has decreased by 7.69% to $12.0. Recent analyst actions include lowered ratings and price targets by Piper Sandler and Stephens & Co. Health Catalyst shows positive revenue growth but faces challenges with a net margin of -17.81% and a debt-to-equity ratio of 0.7.
August 26, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Health Catalyst (HCAT) has received mixed analyst ratings, with a decrease in the average 12-month price target to $12.0. Analysts from Piper Sandler and Stephens & Co. have lowered their ratings and price targets. Despite a positive revenue growth rate of 3.67%, the company faces challenges with a net margin of -17.81% and a debt-to-equity ratio of 0.7.
The mixed analyst ratings and lowered price targets suggest uncertainty in the short-term outlook for HCAT. The positive revenue growth is a positive sign, but the challenges in net margin and debt management may offset this, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100